In a fourth-quarter conference call, Insmed CEO Will Lewis admitted that it was “audacious” that his company would project sales of newly approved respiratory drug Brinsupri to reach $1 billion in 2026. Then he laid out the case why the
read moreAn untitled letter shared to the agency’s public database this month homes in on certain details of a commercial touting Tremfya’s use in ulcerative colitis. More: FDA untitled letter lambastes efficacy claims in ad for J&J’s Tremfya Source: fierce
read moreAs Enflonsia approaches the one-year anniversary of its approval, Merck is padding the case for a label expansion that could see the protective antibody better match Sanofi and AstraZeneca’s rival infant RSV preventive Beyfortus. More: Merck to seek 2nd-season RSV
read moreAs President Donald Trump attempts to convince Congress to write his Most Favored Nation drug pricing plan into law, he has received pushback from free-market conservatives. An interview with former Biden administration advisor John Barkett helps put the effort in
read more
European Commission backs first ultra‑long‑acting biologic for respiratory disease More: Exdensur approved in EU for severe asthma and CRSwNP Source: News
read more
Move expands iPSC‑derived retinal model portfolio and strengthens position in research More: Axol Bioscience acquires Newcells Biotech ophthalmology unit Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals